ONC BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.…
Industry Peers
BiotechnologyKey Statistics
About BeOne Medicines (NASDAQ: ONC)
›
BeOne Medicines (NASDAQ: ONC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12,000 employees.
The shares were at 390.94 USD on 20 November 2026, up 13.8% over 52 weeks. Its 52-week range is 253.95 USD to 424.66 USD: the price is 7.9% below the high and 53.9% above the low.
At a market capitalisation of 44.66B USD, it trades at 50.1 times trailing earnings and 35.9 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 51% for ONC.
BeOne Medicines reports return on equity of 6.6%, an operating margin of 17.8% and revenue up 33.8% year over year.
It holds more cash than debt, a net cash position of 3.72B USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 27 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 472.77 USD is 20.9% above the current price. The next earnings report is expected on 25 February 2027.